<DOC>
	<DOCNO>NCT02318394</DOCNO>
	<brief_summary>To evaluate safety tolerability MEDI0562 adult subject select advance solid tumor</brief_summary>
	<brief_title>A Phase 1 Study MEDI0562 Adult Subjects With Selected Advanced Solid Tumors</brief_title>
	<detailed_description>This first-time-in-human ( FTiH ) Phase 1 , multicenter , open-label , dose-escalation , dose-expansion study MEDI0562 evaluate safety , tolerability , pharmacokinetics , immunogenicity , pharmacodynamics preliminary anti-tumor activity adult subject select advance solid tumor .</detailed_description>
	<criteria>Subjects must confirm advanced solid tumor progress , refractory , intolerant standard therapy appropriate tumor type . Subjects receive 3 prior line therapy recurrent metastatic disease include standard care investigational therapy . Subjects must least 1 measurable lesion . Consent provide archive tumor specimen Willingness undergo pretreatment ontreatment biopsy . Adequate organ function . Use highly effective contraception ( female ) male condom plus spermicide ( male ) . Prior treatment TNFRSF agonists . Subjects receive certain prior immunotherapy toxicity relate prior immunotherapy may permit enroll . Must require use additional immunosuppression corticosteroid management adverse event . History severe allergic reaction unknown allergen component study drug formulation . Receipt conventional investigational anticancer therapy within 28 day prior first dose MEDI0562 . Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . Unresolved toxicity prior anticancer therapy . Any condition , opinion investigator sponsor , would interfere evaluation investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>advanced solid tumor ; immunotherapy ; OX40 ; immuno-oncology</keyword>
</DOC>